🔴 Neurosense Therapeutics is trading 10.24% down in pre-market after its 1-for-20 reverse stock split

Neurosense Therapeutics is trading 10.24% down now at $6.31 after a highly volatile session following its 1-for-20 reverse stock split, effective September 14, 2026.

• The split substantially reduced outstanding shares and introduced a new CUSIP, potentially amplifying trading swings.
• No new company-specific announcement clearly explains the September 16 pre-market decline; broader markets are modestly higher, so macro sentiment does not appear to be the primary driver.